Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Pri

-- C4 Therapeutics has an average rating of outperform and price targets ranging from $1 to $84, according to analysts polled by Capital IQ.


Price: 2.84, Change: +0.5, Percent Change: +21.37
...

Related Keywords

, Therapeutics Inc , Protein Degrader Optimizer , Markets ,